In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib
Crossref DOI link: https://doi.org/10.1007/s10549-015-3504-2
Published Online: 2015-07-21
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chakraborty, Ashok K.
Zerillo, Cynthia
DiGiovanna, Michael P.
Funding for this research was provided by:
Pfizer
Connecticut Breast Health Initiative
Text and Data Mining valid from 2015-07-21